Takeda Looks To Ride 'Wave 1' To JPY5tn Target
12 NMEs Set For Mid-Term Launch
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.
You may also be interested in...
Join us for an audio catch-up of the past week's main biopharma events as brought to you by Scrip's global team, in this mini podcast version of Five Must-Know Things.
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.